Title:Role of β-blockers in Preventing Heart Failure and Major Adverse
Cardiac Events Post Myocardial Infarction
Volume: 19
Issue: 4
Author(s): Nishant Johri*, Prithpal S. Matreja, Aditya Maurya, Shivani Varshney and Smritigandha
Affiliation:
- Department of Pharmacy Practice, Teerthanker Mahaveer College of Pharmacy, Moradabad, Uttar Pradesh, India
Keywords:
Cardiovascular disease, HFrEF, CAD, LVEF, AMI, IHD.
Abstract: β-blockers have been widely utilized as a part of acute myocardial infarction (AMI)
treatment for the past 40 years. Patients receiving β-adrenergic blockers for an extended period following
myocardial infarction have a higher chance of surviving. Although many patients benefited
from β-blockers, many do not, including those with myocardial infarction, left ventricle dysfunction,
chronic pulmonary disease, and elderly people. In individuals with the post-acute coronary
syndrome and normal left ventricular ejection fraction (LVEF), the appropriate duration of betablocker
therapy is still unknown. There is also no time limit for those without angina and those
who do not need β-blockers for arrhythmia or hypertension. Interestingly, β-blockers have been
prescribed for more than four decades. The novel mechanism of action on cellular compartments
has been found continually, which opens a new way for their potential application in cardiac failure
and other cardiac events like post-myocardial infarction. Here, in this review, we studied β-blocker
usage in these circumstances and the current recommendations for β-blocker use from clinical
practice guidelines.
